β Scribed by Marianne K. DeGorter; Richard B. Kim
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The efficacy of specifically targeted anti-viral therapy for hepatitis C virus (HCV) (STAT-C), including HCV protease and polymerase inhibitors, is limited by the presence of drugspecific viral resistance mutations within the targeted proteins. Genetic diversity within these viral proteins also evol
We herein report a novel double pro-drug approach applied to the anti-HCV agent 2'-beta-C-methyl guanosine. A phosphoramidate ProTide motif and a 6-O-methoxy base pro-drug moiety are combined to generate lipophilic prodrugs of the monophosphate of the guanine nucleoside. Modification of the ester an
hronic hepatitis C virus (HCV) infection affects a large number of patients worldwide. While our current therapies (Table ) are effective in approximately 50% of patients, therapy is costly, prolonged, and associated with significant side effects, and it is not suitable for certain groups of patient